Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of ...
Hosted on MSN
Early Promise for PI3K Inhibitor in Brain Metastases
HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in ...
Rakovina Therapeutics Inc., a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, has announced impressive results from its AI-enabled ATR program at the recent ...
Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
For more details about SABCS please visit: https://www.sabcs.org/.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback